Arcus Biosciences annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Arcus Biosciences Debt-to-Equity Ratio Growth & History (RCUS)
Arcus Biosciences's debt-to-equity ratio was 0.31 for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.31 | −0.01 | −4.28% |
| 2024 | 2024-12-31 | 0.33 | 0.07 | +25.17% |
| 2023 | 2023-12-31 | 0.26 | 0.07 | +36.56% |
| 2022 | 2022-12-31 | 0.19 | 0.06 | +42.20% |
| 2021 | 2021-12-31 | 0.13 | 0.10 | +273.83% |
| 2020 | 2020-12-31 | 0.04 | — | — |
Arcus Biosciences quarterly debt-to-equity ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.25 | 0.05 | +23.75% |
| Q1 2026 | 2026-03-31 | 0.22 | 0.10 | +90.85% |
| Q4 2025 | 2025-12-31 | 0.31 | −0.01 | −4.28% |
| Q3 2025 | 2025-09-30 | 0.25 | 0.15 | +148.00% |
| Q2 2025 | 2025-06-30 | 0.20 | 0.18 | +1046.13% |
| Q1 2025 | 2025-03-31 | 0.11 | 0.10 | +626.25% |
| Q4 2024 | 2024-12-31 | 0.33 | 0.07 | +25.17% |
| Q3 2024 | 2024-09-30 | 0.10 | 0.09 | +493.12% |
| Q2 2024 | 2024-06-30 | 0.02 | — | — |
| Q1 2024 | 2024-03-31 | 0.02 | — | — |
| Q4 2023 | 2023-12-31 | 0.26 | 0.07 | +36.56% |
| Q3 2023 | 2023-09-30 | 0.02 | −0.15 | −89.85% |
| Q4 2022 | 2022-12-31 | 0.19 | 0.06 | +42.20% |
| Q3 2022 | 2022-09-30 | 0.17 | 0.08 | +78.97% |
| Q2 2022 | 2022-06-30 | 0.16 | 0.08 | +88.13% |
| Q1 2022 | 2022-03-31 | 0.14 | 0.12 | +551.22% |
| Q4 2021 | 2021-12-31 | 0.13 | 0.10 | +273.83% |
| Q3 2021 | 2021-09-30 | 0.10 | — | — |
| Q2 2021 | 2021-06-30 | 0.09 | — | — |
| Q1 2021 | 2021-03-31 | 0.02 | — | — |
| Q4 2020 | 2020-12-31 | 0.04 | — | — |
Arcus Biosciences debt-to-equity ratio trends
Over the last five fiscal years, Arcus Biosciences's debt-to-equity ratio increased from 0.04 to 0.31, a change of 0.28. The latest reported quarter, Q2 2026, shows 0.25.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗Community posts
Arcus sets $17.50 share price for $250 million equity financing
Arcus Biosciences ($RCUS) priced an underwritten public offering of 14,285,715 new common shares at $17.50 apiece, targeting approximately $250 million in gross proceeds. The company is selling all of the shares, so the financing would add ...
Arcus reports additional kidney-cancer data supporting casdatifan development
Arcus Biosciences ($RCUS) released additional results from the ARC-20 program evaluating casdatifan in kidney cancer. Across pooled monotherapy cohorts involving 121 heavily pretreated patients, median overall survival was 35 months, median ...
